Key Takeaway: The NPC002 trial evaluates the efficacy of Arimoclomol combined with Miglustat over 12 months. This double-blind, randomized, placebo-controlled study is set to present its findings at the 22nd Annual WORLDSymposium. The results may provide insights into effective treatments for patients.
Price reaction · baseline $9.16 (2026-02-03T19:59:00.000Z) · hit during market hours · clean, no other ZVRA news in the window
day 0 close · peak
0%
Market Sentiment Analysis
POSITIVE FACTORS
The trial shows promising efficacy results for Arimoclomol.
Combination therapy with Miglustat may enhance treatment outcomes.
The study is part of a recognized annual symposium.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Publications and Presentations
Efficacy of Arimoclomol Combined With Miglustat at Months 3, 6, 9 and 12 of the Double-Blind, Randomized, Placebo-Controlled NPC002 Trial
22nd Annual WORLDSymposium - 02/03/2026
Download PDF
Download PDF
Frequently Asked Questions
What is the NPC002 trial about?
The NPC002 trial evaluates the efficacy of Arimoclomol combined with Miglustat.
When will the NPC002 trial results be presented?
The results will be presented at the 22nd Annual WORLDSymposium.
What type of study is the NPC002 trial?
It is a double-blind, randomized, placebo-controlled study.
What are the expected outcomes of the trial?
The trial aims to provide insights into effective treatments for patients.